PT - JOURNAL ARTICLE AU - Simon Risanger AU - Bismark Singh AU - David Morton AU - Lauren Ancel Meyers TI - Selecting pharmacies for COVID-19 testing to ensure access AID - 10.1101/2020.09.17.20185090 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.17.20185090 4099 - http://medrxiv.org/content/early/2020/09/18/2020.09.17.20185090.short 4100 - http://medrxiv.org/content/early/2020/09/18/2020.09.17.20185090.full AB - Rapid diagnostic testing for COVID-19 is key to guiding social distancing orders and containing emerging disease clusters by contact tracing and isolation. However, communities throughout the US do not yet have adequate access to tests. Pharmacies are already engaged in testing, but there is capacity to greatly increase coverage. Using a facility location optimization model and willingness-to-travel estimates from US National Household Travel Survey data, we find that if COVID-19 testing became available in all US pharmacies, an estimated 94% of the US population would be willing to travel to obtain a test, if warranted. Whereas the largest chain provides high coverage in densely populated states, like Massachusetts, Rhode Island, New Jersey, and Connecticut, independent pharmacies would be required for sufficient coverage in Montana, South Dakota, and Wyoming. If only 1,000 pharmacies in the US are selected to provide testing, judicious selection, using our optimization model, provides estimated access to 29 million more people than selecting pharmacies simply based on population density. COVID-19 testing through pharmacies can improve access across the US. Even if only few pharmacies offer testing, judicious selection of specific sites can simplify logistics and improve access.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge financial support from the National Institutes of Health under Grant NIH R01 AI151176 and Grant NIH U01 GM087791, the U.S. Department of Homeland Security under Grant 2017-ST-061-QA0001 and Tito's Handmade Vodka. The views and conclusions contained in this document are those of the authors and should not be interpreted as necessarily representing the official policies, either expressed or implied, of the U.S. Department of Homeland Security.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable to the research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesZIP Code Tabulation Areas and corresponding 2010 population counts, centroid coordinates, and land areas are openly available by the US Census Bureau. National Household Travel Survey data used to estimated willingness to travel is openly available from the US Department of Transportation. The national dataset for operating pharmacies in the US was produced by InfoGroup and Amazon Web Services in coordination with Esri's national COVID-19 response team and shared with us for this study.